Abstract:Objective Evidence-based characterization of the diagnostic and prognostic value of the hematological and immunological markers related to the epidemic of Coronavirus Disease 2019 (COVID-19) is critical to understand the clinical course of the infection and to assess in development and validation of biomarkers. Methods Based on systematic search in Web of Science, PubMed, Scopus, and Science Direct up to April 22, 2020, a total of 52 eligible articles with 6,320 laboratory-confirmed COVID-19 cohorts were inclu… Show more
“…Among laboratory tests, elevated neutrophil-to-lymphocyte ratio, but not elevated levels of lactate dehydrogenase, C-reactive protein, or D-dimer, were associated with increased mortality. In contrast, decreased absolute lymphocyte counts were associated with increased mortality ( Supplemental Figure 1 and Supplemental Table 2 ), consistent with previous reports ( 22 , 23 ). Administration of anticoagulation was associated with reduced mortality ( Supplemental Figure 1 and Supplemental Table 2 ).…”
are employees of and own stock in BioAegis Therapeutics, Inc. which is developing recombinant human plasma gelsolin for potential clinical use. Other authors have declared that no conflict of interest exists.
“…Among laboratory tests, elevated neutrophil-to-lymphocyte ratio, but not elevated levels of lactate dehydrogenase, C-reactive protein, or D-dimer, were associated with increased mortality. In contrast, decreased absolute lymphocyte counts were associated with increased mortality ( Supplemental Figure 1 and Supplemental Table 2 ), consistent with previous reports ( 22 , 23 ). Administration of anticoagulation was associated with reduced mortality ( Supplemental Figure 1 and Supplemental Table 2 ).…”
are employees of and own stock in BioAegis Therapeutics, Inc. which is developing recombinant human plasma gelsolin for potential clinical use. Other authors have declared that no conflict of interest exists.
“… 22 The influence of WBC and CRP has been explored in other publications showing that increases in WBC counts are found in patients with COVID-19 admitted to the ICU while CRP has been observed as a predictor of respiratory failure and thrombotic complications. 23-25 In our series, we found that WBC and CRP were found in patients admitted to the ICU and those with poor outcome. Underlying comorbidities and hospital immobilization, which are known risk factors for venous thrombosis, 26 were present in most of our patients, suggesting that the risk of thrombosis in patients with COVID-19 is likely multifactorial.…”
Objectives
Patients with coronavirus disease 2019 (COVID-19) have thromboembolic complications. Assessment of coagulation and other markers could be useful to understand their coagulopathy.
Methods
We performed a retrospective study of inflammatory and coagulation parameters, including prothrombin fragment 1.2 (PF1.2), thrombin-antithrombin complexes (TATs), fibrin monomers, and D-dimer, in hospitalized patients with COVID-19. We compared the markers in patients with thrombosis, admission to the intensive care unit (ICU), and poor outcome.
Results
Of the 81 patients, 9 (11%) experienced an acute thrombotic event (4 with pulmonary embolism, 3 with venous thrombosis, and 2 with stroke). PF1.2 was elevated in 32 (39%) patients, TATs in 54 (67%), fibrin monomers in 49 (60%), and D-dimer in 76 (94%). Statistically significant elevation in PF1.2 and TATs was seen in patients admitted to the ICU, while D-dimer and fibrin monomers were significantly elevated in patients with poor outcomes. The presence of multiple abnormal coagulation parameters was associated with ICU admission. Other parameters with statistically significant results included abnormal WBC counts and elevated C-reactive protein, which were associated with ICU admission and poor outcomes.
Conclusions
Our data demonstrate that abnormalities of biomarkers of hemostasis activation and inflammatory markers are associated with poor outcomes in patients with COVID-19.
“…These findings in patients with a known history of gynecologic cancer are consistent with prior studies of inflammatory, hematologic, and coagulation markers in COVID-19 infection. Two independent meta-analyses of inflammatory markers in COVID-19 infection among the general population have reported significantly higher inflammatory markers in patients with severe COVID-19 and COVID-19 mortality, including CRP, ESR, ferritin, procalcitonin, and IL-6 [9,21,22]. One meta-analysis also found significant associations between hematologic markers and COVID-19 severity and death, including WBC and D-dimer.…”
• Ferritin, procalcitonin, and CRP may have prognostic value for severe COVID-19 infection in gynecologic cancer patients. • Elevated admission white blood cell count, lactate, and creatinine may also be prognostic of severe COVID-19 disease. • D-dimer levels do not appear to be predictive of severe COVID-19 infection in patients with gynecologic cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.